S100 proteins in the pathogenesis and diagnosis of inflammatory bowel disease

Expert Review of Clinical Immunology

Volumn 2, Issue 3, 2006, Pages 471-480

  Leach, Steven T ^a   Day, Andrew S ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALBUMIN; ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; CALPROTECTIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; FERRITIN; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN S 100; PSORIASIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ABDOMINAL SCINTISCANNING; AGE; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; BARIUM MEAL; BLOODY DIARRHEA; BORRELIA BURGDORFERI; CANDIDA ALBICANS; CARCINOGENESIS; CLINICAL FEATURE; COLON CARCINOMA; COLONOSCOPY; CROHN DISEASE; DIAGNOSTIC VALUE; DIARRHEA; DISEASE MARKER; ECHOGRAPHY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; ESCHERICHIA COLI; FECES ANALYSIS; GROWTH DISORDER; HEREDITY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFECTION RESISTANCE; INTESTINE BIOPSY; INTESTINE ENDOSCOPY; INTESTINE FLORA; LISTERIA MONOCYTOGENES; MEDICAL ASSESSMENT; MYCOBACTERIUM PARATUBERCULOSIS; NEUTROPHIL CHEMOTAXIS; NUTRITIONAL DEFICIENCY; PATHOGENESIS; PROTEIN FAMILY; PROTEIN FUNCTION; PSORIASIS; RELIABILITY; REVIEW; SEX DIFFERENCE; STAPHYLOCOCCUS AUREUS; ULCERATIVE COLITIS; WEIGHT REDUCTION;

EID: 33748487413     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.3.471     Document Type: Review

References (122)

1. Griffiths AM, Buller HB. Inflammatory Bowel Diseases. In: Pediatric Gastorintestinal Disease. Walker WA, Hamilton JR, Watkins JB, Durie PR, Walker-Smith JA (Eds). BC Decker, Hamilton Ontario, Canada 613-652 (2000).
2. Auvin S, Molinie F, Gower-Rousseau C et al. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988-1999). J. Pediatr. Gastroenterol. Nutr. 41(1), 49-55 (2005).
3. Elliott DE, Summers RW, Weinstock JV. Helminths and the modulation of mucosal inflammation. Curr. Opin. Gastroenterol. 21(1), 51-58 (2005).
4. Grimm MC, Pavli P. NOD2 mutations and Crohn's disease: are Paneth cells and their antimicrobial peptides the link? Gut 53(11), 1558-1560 (2004).
5. Catto-Smith AG, Cameron D, Rerksuppaaphol SI. Increasing incidence of Crohn's disease in Victoria, Australia. Gastroenterology 124(A515) (2003).
6. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm. Bowel Dis. 10(5), 646-651 (2004).
7. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 108(4), 1056-1067 (1995).
8. Day AS, Whitten KE, de Jong NSH. Nutrition and nutritional management of Crohn's disease in children and adolescents. Curr. Nutr. Food Sci. (2), 3-14 (2006).
9. Lemberg DA, Bohane TD, Moore D, Hirte C, Day AS. Changing features at presentation in Australian children with IBD. J. Pediatr. Gastroenterol. Nutr. 39, S308 (2004).
10. Barton JR, Ferguson A. Clinical features, morbidity and mortality of Scottish children with inflammatory bowel disease. QJ Med. 75(277), 423-439 (1990).
11. Heikenen JB, Werlin SL, Brown CW, Balint JP. Presenting symptoms and diagnostic lag in children with inflammatory bowel disease. Inflamm. Bowel Dis. 5(3), 158-160 (1999).
12. Pimentel M, Chang M, Chow EJ et al. Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am. J. Gastroenterol. 95(12), 3458-3462 (2000).
13. Spray C, Debelle GD, Murphy MS. Current diagnosis, management and morbidity in paediatric inflammatory bowel disease. Acta Paediatr. 90(4), 400-405 (2001).
14. Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 18(2), 165-173 (1994).
15. Simon D. Puberty in chronically diseased patients. Horm. Res. 57(Suppl. 2), 53-56 (2002).
16. Alemzadeh N, Rekers-Mombarg LT, Mearin ML et al. Adult height in patients with early onset of Crohn's disease. Gut 51(1), 26-29 (2002).
17. Mamula P, Telega GW, Markowitz JE et al. Inflammatory bowel disease in children 5 years of age and younger. Am. J. Gastroenterol. 97(8), 2005-2010 (2002).
18. Buller HA. Problems in diagnosis of IBD in children. Neth. J. Med. 50(2), S8-S11 (1997).
19. Rickards H, Prendergast M, Booth IW. Psychiatric presentation of Crohn's disease. Diagnostic delay and increased morbidity. Br. J. Psychiatry 164(2), 256-261 (1994).
20. Baumann H. Electrophoretic analysis of acute-phase plasma proteins. Methods Enzymol. 163, 566-594 (1988).
21. Hyams JS, Mandel F, Ferry GD et al. Relationship of common laboratory parameters to the activity of Crohn's disease in children. J. Pediatr. Gastroenterol. Nutr. 14(2), 216-222 (1992).
22. Griffths AM, Drobnies A, Soldin SJ, Hamilton JR. Enteric protein loss measured by fecal α 1-antitrypsin clearance in the assessment of Crohn's disease activity: a study of children and adolescents. J. Pediatr. Gastroenterol. Nutr. 5(6), 907-911 (1986).
23. McAlindon ME, Mahida YR. Pro-inflammatory cytokines in inflammatory bowel disease. Aliment Pharmacol. Ther. 10(Suppl. 2), 72-74 (1996).
24. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337(15), 1029-1035 (1997).
25. Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J. Clin. Pathol. 46(8), 757-760 (1993).
26. Saiki T, Mitsuyama K, Toyonaga A, Ishida H, Tanikawa K. Detection of pro-and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand. J. Gastroenterol. 33(6), 616-622 (1998).
27. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115(1), 182-205 (1998).
28. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411(6837), 603-606 (2001).
29. Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278(8), 5509-5512 (2003).
30. Vavricka SR, Musch MW, Chang JE et al. hPepT1 transports muramyl dipeptide, activating NF-κB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 127(5), 1401-1409 (2004).
31. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5(8), 800-808 (2004).
32. Wehkamp J, Harder J, Weichenthal M et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal α-defensin expression. Gut 1658-1664 (2004).
33. Levine A, Karban A, Eliakim R et al. A polymorphism in the TNF-α promoter gene is associated with pediatric onset and colonic location of Crohn's disease. Am. J. Gastroenterol. 100(2), 407-413 (2005).
34. Nemetz A, Nosti-Escanilla MP, Molnar T et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 49(6), 527-531 (1999).
35. Tamura K, Fukuda Y, Sashio H et al. IL18 polymorphism is associated with an increased risk of Crohn's disease. J. Gastroenterol. 37(Suppl. 14), 111-116 (2002).
36. Klein W, Tromm A, Folwaczny C et al. A polymorphism of the bactericidal/ permeability increasing protein (BPI) gene is associated with Crohn's disease. J. Clin. Gastroenterol. 39(4), 282-283 (2005).
37. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am. J. Gastroenterol. 92(Suppl. 12), S5-S11 (1997).
38. Sartor RB. Enteric microbiota in IBD - pathogens or commensals. Inflamm. Bowel Dis. (3), 230-235 (1997).
39. Didierlaurent A, Sirard JC, Kraehenbuhl JP, Neutra MR. How the gut senses its content. Cell Microbiol. 4(2), 61-72 (2002).
40. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 51, 289-298 (2000).
41. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous? Aliment Pharmacol. Ther. 16(12), 1997-2015 (2002).
42. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun. 322(4), 1111-1122 (2004).
43. 2+-dependent regulator protein in inflammatory process. J. Mol. Biol. 316(2), 265-276 (2002).
44. Hunter MJ, Chazin WJ. High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J. Biol. Chem. 273(20), 12427-12435 (1998).
45. Bengis-Garber C, Gruener N. Calcium-binding myeloid protein (P8,14) is phosphorylated in fMet-Leu-Phe-stimulated neutrophils. J. Leukoc. Biol. 54(2), 114-118 (1993).
46. Murao S, Collart FR, Huberman E. A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases. J. Biol. Chem. 264(14), 8356-8360 (1989).
47. Roth J, Burwinkel F, van den Bos C et al. MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner. Blood 82(6), 1875-1883 (1993).
48. Sopalla C, Leukert N, Sorg C, Kerkhoff C. Evidence for the involvement of the unique C-tail of S100A9 in the binding of arachidonic acid to the heterocomplex S100A8/A9. Biol. Chem. 383(12), 1895-1905 (2002).
49. Brun JG, Cuida M, Jacobsen H et al. Sjogren's syndrome in inflammatory rheumatic diseases: analysis of the leukocyte protein calprotectin in plasma and saliva. Scand. J. Rheumatol. 23(3), 114-118 (1994).
50. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J. Immunol. 170(6), 3233-3242 (2003).
51. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol. Pharm. Bull. 26(6), 753-760 (2003).
52. Brun JG, Haland G, Haga HJ, Fagerhol MK, Jonsson R. Effects of calprotectin in avridine-induced arthritis. Apmis 103(3), 233-240 (1995).
53. Sohnle PG, Collins-Lech C, Wiessner JH. The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. J. Infect. Dis. 164(1), 137-142 (1991).
54. Sohnle PG, Hunter MJ, Hahn B, Chazin WJ. Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14). J. Infect. Dis. 182(4), 1272-1275 (2000).
55. Sohnle PG, Collins-Lech C, Wiessner JH. Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils. J. Infect. Dis. 163(1), 187-192 (1991).
56. Brandtzaeg P, Gabrielsen TO, Dale I et al. The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Adv. Exp. Med. Biol. 371A, 201-206 (1995).
57. Lulloff SJ, Hahn BL, Sohnle PG. Fungal susceptibility to zinc deprivation. J. Lab. Clin. Med. 144(4), 208-214 (2004).
58. Lusitani D, Malawista SE, Montgomery RR. Calprotectin, an abundant cytosolic protein from human polymorphonuclear leukocytes, inhibits the growth of Borrelia burgdorferi. Infect. Immun. 71(8), 4711-4716 (2003).
59. Steinbakk M, Naess-Andresen CF, Lingaas E et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 336(8718), 763-765 (1990).
60. Nisapakultorn K, Ross KF, Herzberg MC. Calprotectin expression inhibits bacterial binding to mucosal epithelial cells. Infect. Immun. 69(6), 3692-3696 (2001).
61. Yang TH, Tzeng S, Cheng I et al. Identification of the mouse calcium-binding proteins, MRP 8 and MRP 14, in Schistosoma mansoni-induced granulomas: biochemical and functional characterization. J. Leukoc. Biol. 61(3), 258-266 (1997).
62. Kurata A, Terado Y, Schulz A, Fujioka Y, Franke FE. Inflammatory cells in the formation of tumor-related sarcoid reactions. Hum. Pathol. 36(5), 546-554 (2005).
63. Gottsch JD, Eisinger SW, Liu SH, Scott AL. Calgranulin C has filariacidal and filariastatic activity. Infect. Immun. 67(12), 6631-6636 (1999).
64. Cole AM, Kim YH, Tahk S et al. Calcitermin, a novel antimicrobial peptide isolated from human airway secretions. FEBS Lett. 504(1-2), 5-10 (2001).
65. Harrison CA, Raftery MJ, Walsh J et al. Oxidation regulates the inflammatory properties of the murine S100 protein S100A8. J. Biol. Chem. 274(13), 8561-8569 (1999).
66. Raftery MJ, Yang Z, Valenzuela SM, Geczy CL. Novel intra- and inter-molecular sulfinamide bonds in S100A8 produced by hypochlorite oxidation. J. Biol. Chem. 276(36), 33393-33401 (2001).
67. Banan A, Fields JZ, Talmage DA, Zhang Y, Keshavarzian A. PKC-β1 mediates EGF protection of microtubules and barrier of intestinal monolayers against oxidants. Am. J. Physiol. Gastrointest. Liver Physiol. 281(3), G833-G847 (2001).
68. Banan A, Fields JZ, Zhang Y, Keshavarzian A. iNOS upregulation mediates oxidant-induced disruption of F-actin and barrier of intestinal monolayers. Am. J. Physiol. Gastrointest. Liver Physiol. 280(6), G1234-G1246 (2001).
69. 2+ in EGF protection of microtubules and intestinal barrier against oxidants. Am. J. Physiol. Gastrointest. Liver Physiol. 280(5), G828-G843 (2001).
70. Keshavarzian A, Banan A, Farhadi A et al. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut 52(5), 720-728 (2003).
71. Xu K, Geczy CL. IFN-γ and TNF regulate macrophage expression of the chemotactic S100 protein S100A8. J. Immunol. 164(9), 4916-4923 (2000).
72. Xu K, Yen T, Geczy CL. IL-10 up-regulates macrophage expression of the S100 protein S100A8. J. Immunol. 166(10), 6358-6366 (2001).
73. Hsu K, Passey RJ, Endoh Y et al. Regulation of S100A8 by glucocorticoids. J. Immunol. 174(4), 2318-2326 (2005).
74. Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull. Eur. Physiopathol. Respir. 16(Suppl.) 273-282 (1980).
75. 2+-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn's disease. Digestion 56(5), 406-414 (1995).
76. Mork G, Schjerven H, Mangschau L, Soyland E, Brandtzaeg P. Proinflammatory cytokines upregulate expression of calprotectin (L1 protein, MRP-8/MRP-14) in cultured human keratinocytes. Br. J. Dermatol. 149(3), 484-491 (2003).
77. Brandtzaeg P, Dale I, Fagerhol MK. Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. I. Comparison with other leukocyte markers by paired immunofluorescence and immunoenzyme staining. Am. J. Clin. Pathol. 87(6), 681-699 (1987).
78. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am. J. Pathol. 159(6), 2001-2009 (2001).
79. Nikolaus S, Bauditz J, Gionchetti P et al. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 42(4), 470-476 (1998).
80. 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease. Gastroenterology 85(6), 1333-1339 (1983).
81. 111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 34(1), 50-54 (1999).
82. Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J. Gastroenterol. Hepatol. 18(7), 756-762 (2003).
83. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotettin in feces. A methodologic study. Scand. J. Gastroenterol. 27(9), 793-798 (1992).
84. Alic M. Is fecal calprotectin the next standard in inflammatory bowel disease activity tests? Am. J. Gastroenterol. 94(11), 3370-3371 (1999).
85. Bunn SK, Bisset WM, Main MJ et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 33(1), 14-22 (2001).
86. Carroccio A, Iacono G, Cottone M et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin. Chem. 49(6 Pt 1), 861-867 (2003).
87. Costa F, Mumolo MG, Bellini M et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis. 35(9), 642-647 (2003).
88. Lugering N, Stoll R, Schmid KW et al. The myeloic related protein MRP8/ 14 (27E10 antigen) - usefulness as a potential marker for disease activity in ulcerative colitis and putative biological function. Eur. J. Clin. Invest. 25(9), 659-664 (1995).
89. Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 34(10), 1357-1363 (1993).
90. Tibble J, Teahon K, Thjodleifsson B et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 47(4), 506-513 (2000).
91. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 32(2), 171-177 (2001).
92. Tibble J, Sigthorsson G, Foster R et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49(3), 402-408 (2001).
93. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 39(10), 1017-1020 (2004).
94. 111 in granulocyte excretion. Digestion 33(2), 74-79 (1986).
95. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119(1), 15-22 (2000).
96. Costa F, Mumolo MG, Ceccarelli L et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 54(3), 364-368 (2005).
97. Thjodleifsson B, Sigthorsson G, Cariglia N et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 124(7), 1728-1737 (2003).
98. Campeotto F, Butel MJ, Kalach N et al. High faecal calprotectin concentrations in newborn infants. Arch. Dis. Child Fetal Neonatal Ed. 89(4), F353-F355 (2004).
99. Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 91(1), 45-50 (2002).
100. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J. Pediatr. Gastroenterol. Nutr. 34(3), 323-324; author reply 324-325 (2002).
101. Berni Canani R, Rapacciuolo L, Romano MT et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig. Liver Dis. 36(7), 467-470 (2004).
102. Carroll D, Corfield A, Spicer R, Cairns P. Faecal calprotectin concentrations and diagnosis of necrotising enterocolitis. Lancet 361(9354), 310-311 (2003).
103. Laforgia N, Baldassarre ME, Pontrelli G et al. Calprotettin levels in meconium. Acta Paediatr. 92(4), 463-466 (2003).
104. Miranda LP, Tao T, Jones A et al. Total chemical synthesis and chemotactic activity of human S100A12 (EN-RAGE). FEBS Lett. 488(1-2), 85-90 (2001).
105. Dell'Angelica EC, Schleicher CH, Santome JA. Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J. Biol. Chem. 269(46), 28929-28936(1994).
106. Guignard F, Mauel J, Markert M. Identification and characterization of a novel human neutrophil protein related to the S100 family. Biochim. J. 309(Pt 2), 395-401 (1995).
107. Yang Z, Tao T, Raftery MJ et al. Proinflammatory properties of the human S100 protein S100A12. J. Leukoc. Biol. 69(6), 986-994 (2001).
108. Foell D, Seeliger S, Vogl T et al. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 58(7), 613-617 (2003).
109. Foell D, Wittkowski H, Hammerschmidt I et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 50(4), 1286-1295 (2004).
110. Foell D, Kucharzik T, Kraft M et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52(6), 847-853 (2003).
111. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim. Biophys. Acta 1450(3), 191-231 (1999).
112. Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97(7), 889-901 (1999).
113. Neeper M, Schmidt AM, Brett J et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267(21), 14998-15004 (1992).
114. Yan SD, Chen X, Fu J et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382(6593), 685-691 (1996).
115. Hori O, Brett J, Slattery T et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270(43), 25752-25761 (1995).
116. Hofmann MA, Drury S, Hudson BI et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 3(3), 123-135 (2002).
117. Falcone C, Emanuele E, D'Angelo A et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 25(5), 1032-1037 (2005).
118. Zeng S, Feirt N, Goldstein M et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 39(2), 422-432 (2004).
119. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum. Mol. Genet. 10(5), 445-456 (2001).
120. El-Rifai W, Moskaluk CA, Abdrabbo MK et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 62(23), 6823-6826 (2002).
121. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment. Pharmacol. Ther. 18(Suppl. 2), 1-5 (2003).
122. Broome AM, Ryan D, Eckert RL. S100 protein subcellular localization during epidermal differentiation and psoriasis. J. Histochem. Cytochem. 51(5), 675-685 (2003).